Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: HIV Infection, Liver Transplant
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Interventions: CLN-049; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 13 more

Conditions: Alport Syndrome
Interventions: RG012; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: La Mesa, California • Los Angeles, California • Riverside, California + 4 more

Conditions: Spinal Cord Injury, Chronic, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Incomplete Spinal Cord Injury
Interventions: Active Comparator: Single Intervention 1, Active Comparator: Single Intervention 2, Respiratory Resistance Exercise; Other · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hiv
Interventions: Cabotegravir Injection [Apretude]; Drug
Lead sponsor: Midway Specialty Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Orlando, Florida • Temple Terrace, Florida • West Palm Beach, Florida

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Genitourinary Syndrome of Menopause, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Autologous Platelet-rich Plasma; Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Human Immunodeficiency Virus, HIV Seropositivity
Interventions: iTransition; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Tourette Syndrome
Interventions: PF-04457845, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Morquio Disease, Mucopolysaccharidosis IV
Interventions: Not listed
Lead sponsor: Nadia Ali, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Myeloproliferative Disorders, Blood Cancer, Myelodysplastic Syndromes
Interventions: Total Lymphoid Irradiation (TLI), Anti-Thymocyte Globulin as Conditioning (ATG); Procedure
Lead sponsor: Stanford University; Other
Eligibility: 49 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes, Obesity, Metabolic Syndrome, Cardiovascular Disease
Interventions: Carbohydrate + Protein, Carbohydrate + Fat, Fiber, Carbohydrate load; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mucopolysaccharidosis IV A, Morquio A Syndrome, MPS IVA
Interventions: BMN 110 - Weekly, BMN 110 - Every Other Week; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Oakland, California • Orange, California + 7 more

Conditions: Polycystic Ovary Syndrome
Interventions: Not listed
Lead sponsor: Georgia Reproductive Specialists; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Interventions: Pembrolizumab, Mogamulizumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Myelodysplastic Syndromes
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2052
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sepsis
Interventions: Nelfinavir; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: HIV, Infectious
Interventions: darunavir, ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 38 more

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 11
States / cities: Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Conditions: PMDD, Premenstrual Dysphoric Disorder (PMDD), Premenstrual Syndrome-PMS, Premenstrual Syndrome, Menstrual Cycle
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Patellofemoral Pain Syndrome
Interventions: Lumbopelvic manipulation; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine phosphate, Melphalan, Mycophenolate Mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation, Fractionated total body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 0 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 2
States / cities: Phoenix, Arizona • Duarte, California

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Metabolic response to protein source; Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Search by objective public record fields.

Expanding HOPE Liver

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Study of RG-012 in Subjects With Alport Syndrome

Non-Invasive Interventions for Respiratory Recovery in Chronic Spinal Cord Injury

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer

iTransition Development

FAAH Inhibitor Trial for Adults With Tourette Syndrome

Psychological Concomitants of Morquio Syndrome (The MAP Study)

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Glycemic Index - Variability Among Individuals

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

The Impact of Polycystic Ovary Syndrome (PCOS) on Quality of Life and Healthcare Beliefs

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

The Effects of HIV Protease Inhibitors in Severe Sepsis

Safety Study of TPI-287 to Treat CBS and PSP

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Identification and Validation of Epigenetic Biomarkers of PMDD

Effects of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity

AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

Appetite Response to Meals With Different Protein Sources in Women With PCOS